Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,492,461.00 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 114,367 shares of the company’s stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Dianthus Therapeutics Stock Up 2.9%

Dianthus Therapeutics stock traded up $2.46 during mid-day trading on Thursday, hitting $87.02. 56,787 shares of the stock were exchanged, compared to its average volume of 1,060,620. The firm’s fifty day simple moving average is $62.49 and its two-hundred day simple moving average is $47.35. Dianthus Therapeutics, Inc. has a 12 month low of $13.36 and a 12 month high of $88.49. The stock has a market capitalization of $3.87 billion, a price-to-earnings ratio of -21.08 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. As a group, analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on DNTH shares. HC Wainwright increased their target price on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the company a “buy” rating in a report on Monday, March 9th. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price on the stock. Wedbush increased their price objective on Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research report on Tuesday, March 10th. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, William Blair restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $117.30.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Patient Square Capital LP bought a new stake in Dianthus Therapeutics during the third quarter valued at about $4,919,000. Vanguard Group Inc. raised its stake in Dianthus Therapeutics by 13.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,642,198 shares of the company’s stock valued at $64,620,000 after purchasing an additional 196,117 shares during the period. XTX Topco Ltd purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $503,000. Fairmount Funds Management LLC boosted its stake in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock worth $130,138,000 after purchasing an additional 600,000 shares during the period. Finally, Braidwell LP purchased a new stake in Dianthus Therapeutics during the 3rd quarter valued at approximately $32,859,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.